Press
Press releases
- 05/16/2013PharmaMar to present new studies with Yondelis® at ASCO• Two studies that will be presented are especially noteworthy, as Yondelis® was administered as first-line treatment in patients with different types of soft tissue sarcoma. • The ASCO Annual Meeting is one of the world's leading events in cancer research
-
- 05/07/2013PharmaMar completes enrolment for its Phase IIb trial with PM01183 in patients with resistant/refractory ovarian cancer
-
- 04/29/2013Full availability of Yondelis® in combination with Caelyx® for patients with ovarian cancer
-
- 04/25/2013Zeltia obtains 17.6 million euro in EBITDA and continues to increase revenues outside Spain- Of total Group revenue in the quarter, 71% are from overseas. - Cash flow continued to improve and Group debt declined.
-
- 04/11/2013PharmaMar presents five new trials with its marine-based drugs at the Annual Meeting of the American Association for Cancer Research (AACR)
-
- 03/20/2013GENOMICA DEVELOPS NEW DIAGNOSTIC KITS FOR SOMATIC MUTATIONS THAT ARE DETERMINANT IN ANTI-TUMOUR THERAPIESGENOMICA has laid the groundwork for an R&D and innovation project related to its CLART® CMA (Cancer Mutation Analysis) diagnostic kit and has established an agreement with the Molecular Pathology Department of Hvidovre University Hospital in Copenhagen.
-
- 03/19/2013The German subsidiary of PharmaMar presents Science Award for Research into Bone Tumours and Soft Tissue Sarcoma to Dr. Jens Jakob
-
- 02/27/2013Zeltia announces that subsidiary Sylentis has commenced Phase II clinical trials with its compound SYL1001 for treating eye discomfort associated with dry eye syndrome
-
- 02/14/2013Innovation, the key to healthcare reform in Germany and SpainGaspar Casal Foundation and PharmaMar organise an event focusing on German and Spanish healthcare
-
PRESS ARCHIVE